Our objective is to systematically evaluate the therapeutic potential of AAV-mediated FKRP gene delivery and assess the efficacy of the gene replacement therapy for individuals with LGMD2I exhibiting various degrees of disease pathology before a viable treatment option is available. The gene discussed is FKRP; the disease is autosomal recessive limb-girdle muscular dystrophy type 2I.